Drug Search Results
More Filters [+]

Epirubicin

Alternative Names: epirubicin, epidoxorubicin, epirubicine, acid 8, pharmorubicin, ellence
Latest Update: 2024-10-03
Latest Update Note: Clinical Trial Update

Product Description

Epirubicin is used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. Epirubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a603003.html)

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Epirubicin

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Singapore, Spain, Switzerland, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: Alveolar Rhabdomyosarcoma|Bladder Cancer|Breast Cancer|Clear Cell Sarcoma|Leiomyosarcoma|Liposarcoma|Sarcoma, Ewing|Triple Negative Breast Cancer

Phase 2: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Inflammatory Breast Cancer|Muscle Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STRASS 2

P3

Unknown status

Liposarcoma|Leiomyosarcoma

2027-12-16

VESTIGE

P2

Unknown status

Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer

2026-12-06

SJB-SQ-2023123

P3

Recruiting

Breast Cancer

2026-06-30

ROSCO V1.0, 15th October 2014

P3

Unknown status

Breast Cancer

2025-05-26

Recent News Events